Role of vitamin d receptor (vdr) polymorphisms in susceptibility to multiple myeloma in ethnic kashmiri population

Blood Cells, Molecules, and Diseases

Volumn 51, Issue 1, 2013, Pages 56-60

  Shafia, Syed ^a   Qasim, Iqbal ^a   Aziz, Sheikh Aejaz ^a   Bhat, Imtiyaz A ^a   Nisar, Syed ^a   Shah, Zafar Amin ^a  

^a SHER I KASHMIR INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Kashmir; Multiple myeloma; Polymorphism; RFLP; VDR

Indexed keywords

ALBUMIN; CREATININE; VITAMIN D RECEPTOR;

ADULT; ARTICLE; CANCER RISK; CANCER STAGING; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE PREDISPOSITION; DNA POLYMORPHISM; ETHNIC GROUP; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; INDIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECEPTOR GENE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT;

ADULT; AGED; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INDIA; MALE; MIDDLE AGED; MULTIPLE MYELOMA; POLYMORPHISM, GENETIC; RECEPTORS, CALCITRIOL; RISK FACTORS;

EID: 84877117176     PISSN: 10799796     EISSN: 10960961     Source Type: Journal    
DOI: 10.1016/j.bcmd.2013.02.001     Document Type: Article

References (44)

1. Aggarwal R., Ghobrial I.M., Roodman G.D. Chemokines in multiple myeloma. Exp. Hematol. 2006, 34:1289-1295.
2. Jemal A., Murray T., Ward E., et al. Cancer statistics, 2005. CA Cancer J. Clin. 2005, 55:10-30.
3. Roodman G.D. Mechanisms of bone metastasis. N. Engl. J. Med. 2004, 350:1655-1664.
4. Kyle R.A. Multiple myeloma, review of 869 cases. Mayo Clin. Proc. 1975, 50:29-40.
5. Holick M.F. Vitamin D deficiency. N. Engl. J. Med. 2007, 357:266-281.
6. Diamond T., Golombick T., Manoharan A. Vitamin D status may affect the skeletal complications of multiple myeloma. Am. J. Hematol. 2010, 85:302-303.
7. Badros A., Goloubeva O., Terpos E., Milliron T., Baer M.R., Streeten E. Prevalence and significance of vitamin D deficiency in multiple myeloma patients. Br. J. Haematol. 2008, 142:492-494.
8. Bikle D. Nonclassic actions of vitamin D. J. Clin. Endocrinol. Metab. 2009, 94:26-34.
9. Osborne J.E., Hutchinson P.E. Vitamin D and systemic cancer, is this relevant to malignant melanoma?. Br. J. Dermatol. 2002, 147:197-213.
10. Holick M.F. Vitamin D: its role in cancer prevention and treatment. Prog. Biophys. Mol. Biol. 2006, 92:49-59.
11. Garland C.F., Garland F.C., Gorham E.D., Lipkin M., Newmark N., Mohr S.B., Holick M.F. The role of vitamin D in cancer prevention. Am. J. Public Health 2006, 96:252-261.
12. Giovannucci E. The epidemiology of vitamin D and cancer incidence and mortality: a review. Cancer Causes Control 2005, 16:83-95.
13. Park W.H., Seol J.G., Kim E.S., Binderup L., Koeffler H.P., Kim B.K., Lee Y.Y. The induction of apoptosis by a combined 1,25(OH)2D3 analog, EB1089 and TGF-beta1 in NCI-H929 multiple myeloma cells. Int. J. Oncol. 2002, 20:533-542.
14. Park W.H., Seol J.G., Kim E.S., Hyun J.M., Jung C.W., Lee C.C., Binderup L., Koeffler H.P., Kim B.K., Lee Y.Y. Induction of apoptosis by vitamin D3 analogue EB1089 in NCI-H929 myeloma cells via activation of caspase 3 and p38 MAP kinase. Br. J. Haematol. 2000, 109:576-583.
15. Park W.H., Seol J.G., Kim E.S., Jung C.W., Lee C.C., Binderup L., Koeffler H.P., Kim B.K., Lee Y.Y. Cell cycle arrest induced by the vitamin D(3) analog EB1089 in NCI-H929 myeloma cells is associated with induction of the cyclin-dependent kinase inhibitor p27. Exp. Cell Res. 2000, 254:279-286.
16. Kumagai T., O'Kelly J., Said J.W., Koeffler H.P. Vitamin D2 analog 19-nor-1,25 dihydroxyvitamin D2: antitumor activity against leukemia, myeloma, and colon cancer cells. J. Natl. Cancer Inst. 2003, 95:896-905.
17. Baker A.R., McDonnell D.P., Hughes M., Crisp T.M., Mangelsdorf D.J., Haussler M.R., Pike J.W., Shine J., O'Malley B.W. Cloning the expression of full length cDNA encoding human vitamin D receptor. Proc. Natl. Acad. Sci. U. S. A. 1988, 85:3294-3298.
18. Taymans S.E., Pack S., Pak E., et al. The human vitamin D receptor gene (VDR) is localized to region 12 cen-q12 by fluorescent in situ hybridization and radiation hybrid mapping: genetic and physical VDR map. J. Bone Miner. Res. 1999, 14:1163-1166.
19. Uitterlinden Andre' G., Fang Yue, van Meurs Joyce B.J., Pols Huibert A.P., van Leeuwen Johannes P.T.M. Genetics and biology of vitamin D receptor polymorphisms. Gene 2004, 338:143-156.
20. Morrison N.A., Yeoman R., Kelly P.J., Eisman J.A. Contribution of trans-acting factor alleles to normal physiological variability: vitamin D receptor gene polymorphism and circulating osteocalcin. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:6665-6669.
21. Jurutka P.W., Whitfield G.K., Hsieh J.C., Tompson P.D., Haussler C.A., Haussler M.R. Molecular nature of vitamin D receptor and its role in regulation of gene expression. Rev. Endocrinol. Metabol. Disord. 2001, 2:203-216.
22. Arai H., Miyamoto K., Taketani Y., Yamamoto H., Iemori Y., Morita K., Tonai T., Nishisho T., Mori S., Takeda E. A vitamin D receptor gene polymorphism in the translation initiation codon: effect on protein activity and relation to bone mineral density in Japanese women. J. Bone Miner. Res. 1997, 12:915-921.
23. Peters U., McGlynn K.A., Chatterjee N., Gunter E., Garcia-Closas M., Rothman N., Sinha R. Vitamin D, calcium and vitamin D receptor polymorphism in colorectal adenomas. Cancer Epidemiol. Biomarkers Prev. 2001, 10:1267-1274.
24. Wong H.L., Seow A., Arakawa K., Lee H.P., Yu M.C., Ingles S.A. Vitamin D receptor start codon polymorphism and colorectal cancer risk: effect modification by dietary calcium and fat in Singapore Chinese. Carcinogenesis 2003, 24:1091-1095.
25. Bertherton-Watt D., Given-Wilson R., Mansi J.L., Thomas V., Cater N., Colston K.W. Vitamin D receptor gene polymorphisms are associated with breast cancer risk in a UK Caucasian population. Br. J. Cancer 2001, 85:171-175.
26. Cui J., Shen K., Shen Z., Jiang F., Shen F. Relationship of vitamin D receptor polymorphism with breast cancer. Zhonghua Yi Xue Chuan Xue Za Zhi 2001, 18:286-288.
27. Curran J.E., Vaughan T., Lea R.A., Weinstein S.R., Morrison N.A., Griffiths L.R. Association of vitamin D receptor polymorphism with sporadic breast cancer development. Int. J. Cancer 1999, 83:723-726.
28. Watanabe M., Fukutome K., Muata M., Uemura H., Kubota Y., Kawamura J., Yatani R. Significance of vitamin D receptor gene polymorphism for prostate cancer risk in Japanese. Anticancer. Res. 1999, 19:4511-4514.
29. Furuya Y., Akakura K., Masai M., Ito H. Vitamin D receptor gene polymorphism in Japanese patients with prostate cancer. Endocr. J. 1999, 46:467-470.
30. Roodman G.D. Myeloma bone disease: pathogenesis and treatment. Oncology 2003, 2003(19):983-984.
31. Belch A.R., Bergsagel D.E., Wilson K., et al. Effect of daily etidronate on the osteolysis of multiple myeloma. J. Clin. Oncol. 1991, 9:1397-1402.
32. Kyle R.A., Jowsey J., Kelly P.J., et al. Multiple myeloma bone disease. The comparative effect of sodium fluoride and calcium carbonate or placebo. N. Engl. J. Med. 1975, 293:1334-1338.
33. Visser M., Deeg D.J., Lips P. Low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass (sarcopenia): the Longitudinal Aging Study Amsterdam. J. Clin. Endocrinol. Metab. 2003, 88:37-66.
34. Whitfield G.K., Remus L.S., Jurutka P.W., Zitzer H., Oza A.K., Hope T., Dang H.T.L., Haussler C.A., Galligan M.A., Thatcher M.L., Dominguez C.E., Haussler M.R. Are human vitamin D receptor polymorphisms functionally significant?. Vitamin D Endocrine System, Structural, Biological, Genetic and Clinical Aspects 2000, 817-823. University of California, Riverside, CA. A.W. Norman, R. Bouillon, M. Thomasset (Eds.).
35. Chen W.Y., Bertone-Johnson E.R., Hunter D.J., Willett W.C., Hankinson S.E. Associations between polymorphisms in the vitamin D receptor and breast cancer risk. Cancer Epidemiol. Biomarkers Prev. 2005, 14:2335-2339.
36. Xu Y., Shibata A., McNeal J.E., Stamey T.A., Feldman D., Peehl D.M. Vitamin D receptor start codon polymorphism (Fok1) and prostate cancer progression. Cancer Epidemiol. Biomarkers Prev. 2003, 12:23-27.
37. Cicek M.S., Liu X., Schumacher F.R., Casey G., Witte J.S. Vitamin D receptor genotypes/haplotypes and prostate cancer risk. Cancer Epidemiol. Biomarkers Prev. 2006, 15:2549-2552.
38. Li H., Stampfer M.J., Hollis J.B., Mucci L.A., Gaziano J.M., Hunter D., Giovannucci E.L., Ma J. A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med. 2007, 4:e103.
39. Li C., Liu Z., Wang L.E., Gershenwald J.E., Lee J.E., Prieto V.G., Duvic M., Grimm E.A., Wei Q. Haplotype and genotypes of the VDR gene and cutaneous melanoma risk in non-Hispanic whites in Texas: a case-control study. Int. J. Cancer 2008, 122:2077-2084.
40. Lurie G., Wilkens L.R., Thompson P.J., McDuffie K.E., Carney M.E., Terada K.Y., Goodman M.T. Vitamin D receptor gene polymorphisms and epithelial ovarian cancer risk. Epidemiol. Biomarkers Prev. 2007, 16:2566-2571.
41. Ng A.C., Kumar S.K., Rajkumar S.V., Drake M.T. Impact of vitamin D deficiency on the clinical presentation and prognosis of patients with newly diagnosed multiple myeloma. Am. J. Hematol. 2009, 84:397-400.
42. Greipp P.R., San Miguel J., Durie B.G., Crowley J.J., Barlogie B., Blade J., Boccadoro M., Child J.A., Avet-Loiseau H., Kyle R.A., Lahuerta J.J., Ludwig H., Morgan G., Powles R., Shimizu K., Shustik C., Sonneveld P., Tosi P., Turesson I., Westin J. International staging system for multiple myeloma. J. Clin. Oncol. 2005, 23:3412-3420.
43. Orlandin Premaor M., Vasconcelos Alves G., Beatriz Crossetti L., Weber Furlanetto T. Hyperparathyroidism secondary to hypovitaminosis D in hypoalbuminemic is less intense than in normoalbuminemic patients. Endocrine 2004, 24:47-53.
44. Kostner K., Denzer N., Muller C.S.L., Klein R., Tilgen W., Reichrathi J. The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature. Anticancer. Res. 2009, 29:3511-3536.